SCHEMBL1140159

SCHEMBL1140159

NCC(O)C(=O)Oc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALOX15 P16050 2/20 0.44
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
ELANE P08246 1/20 0.42
TDP1 Q9NUW8 1/20 0.40
SLC1A3 P43003 1/20 0.40
HTR2A P28223 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
ADRA2C P18825 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GABBR2 O75899 1/20 0.39
GABBR1 Q9UBS5 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP19A1 P11511 1/20 0.39
MAPT P10636 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7105263 1.00 ATM (0.46) ATML3MBTL1ALOX15ADRB2ADRB1
SCHEMBL27660502 0.85 ATM (0.44) ATML3MBTL1ALOX15ADRB2ADRB1
SCHEMBL5198959 0.82 ATM (0.47) ATML3MBTL1ALOX15ADRB2ADRB1
SCHEMBL27551102 0.81 ATM (0.46) ATML3MBTL1ALOX15ELANETDP1
SCHEMBL29163224 0.81 ATM (0.46) ATML3MBTL1ALOX15ADRB2ADRB1
SCHEMBL24530374 0.81 ATM (0.46) ATML3MBTL1ALOX15ELANETDP1
SCHEMBL2619547 0.81 ATM (0.50) ATML3MBTL1ADRB2ADRB1ADRB3
SCHEMBL27639690 0.81 ATM (0.46) ATML3MBTL1ALOX15ELANETDP1
SCHEMBL15156036 0.80 CCNC (0.46) ALOX15TDP1HPGDHSD17B10ALDH1A1
SCHEMBL6182569 0.79 CYP1A2 (0.47) ATML3MBTL1ADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575929-B1 THE METHOD FOR PRODUCTION OF SEMI-FINISHED PRODUCTS USEFUL IN SYNTHESIS OF PACLITAXEL AGROPHARM S A (PL) 2007-03-21 EP claimed
EP-1575929-A1 THE METHOD FOR PRODUCTION OF SEMI-FINISHED PRODUCTS USEFUL IN SYNTHESIS OF PACLITAXEL Agropharm S.A. (PL) 2005-09-21 EP claimed
WO-2004056790-A1 THE METHOD FOR PRODUCTION OF SEMI-FINISHED PRODUCTS USEFUL IN SYNTHESIS OF PACLITAXEL AGROPHARM S.A. (PL) 2004-07-08 WO claimed
JP-3083956-A None JP disclosed
CN-105008419-B Photochromic curable composition, cured product thereof, and laminate containing same 株式会社德山 2016-10-12 CN disclosed
CN-105037243-A Paclitaxel side-chain phenyl serine derivative, and preparation method and application thereof UNIV GUIZHOU 2015-11-11 CN disclosed
CN-105008419-A Photochromic curable composition, cured product thereof, and laminate containing same TOKUYAMA CORP 2015-10-28 CN disclosed
US-8299279-B2 Semi-synthetic process for the preparation of taxane derivatives CHATHAM BIOTEC LTD. (CA) 2012-10-30 US disclosed
EP-1383754-B1 PROCESS FOR MAKING TAXANE DERIVATIVES SCINOPHARM TAIWAN LTD (TW) 2011-02-23 EP disclosed
US-20100029957-A1 Semi-Synthetic Process for the Preparation of Taxane Derivatives CHATHAM BRUNSWICK BIOTEC LTD (CA) 2010-02-04 US disclosed
EP-2114908-A1 SEMI-SYNTHETIC PROCESS FOR THE PREPARATION OF TAXANE DERIVATIVES Chatham Biotec Ltd (CA) 2009-11-11 EP disclosed
EP-0690853-A4 TAXANES PREPARED BY BETA-LACTAMS AND AMMONIUM ALKOXIDES UNIV FLORIDA STATE (US) 1996-03-27 EP disclosed
EP-0690853-A1 TAXANES PREPARED BY BETA-LACTAMS AND AMMONIUM ALKOXIDES FLORIDA STATE UNIVERSITY (US) 1996-01-10 EP disclosed
US-5466834-A Taxane antitumor agent FLORIDA STATE UNIVERSITY (US) 1995-11-14 US disclosed
US-5430160-A Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides FLORIDA STATE UNIVERSITY (US) 1995-07-04 US disclosed
WO-1994021623-A1 TAXANES PREPARED BY BETA-LACTAMS AND AMMONIUM ALKOXIDES FLORIDA STATE UNIVERSITY (US) 1994-09-29 WO disclosed
EP-0605637-A4 PREPARATION OF SUBSTITUTED ISOSERINE ESTERS USING METAL ALKOXIDES AND -G(B)-LACTAMS. UNIV FLORIDA STATE (US) 1994-08-24 EP disclosed
EP-0605637-A1 PREPARATION OF SUBSTITUTED ISOSERINE ESTERS USING METAL ALKOXIDES AND $g(b)-LACTAMS FLORIDA STATE UNIVERSITY (US) 1994-07-13 EP disclosed
WO-1993006079-A1 PREPARATION OF SUBSTITUTED ISOSERINE ESTERS USING METAL ALKOXIDES AND β-LACTAMS FLORIDA STATE UNIVERSITY (US) 1993-04-01 WO disclosed
JP-H0383956-A ENANTHIO-SELECTIVE PREPARATION OF PHENYL ISOSERINE DERIVATIVE CENTRE NATL RECH SCIENT (CNRS) 1991-04-09 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029957-A1 Semi-Synthetic Process for the Preparation of Taxane Derivatives WEE1, WEE2, NOTUM ATM 996/4885L3MBTL1 3609/4885ALOX15 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.